The Institute for Clinical and Economic Review (ICER) has posted draft scoping documents that will inform reports on two new drugs for diabetes (types 1 and 2) and asthma. These reports will serve as the basis for the February 12, 2016 public meeting of the California Technology Assessment Forum (CTAF), a core program of ICER. ICER’s reports for CTAF will evaluate the health and economic outcomes of two interventions: insulin degludec (Tresiba®, Novo Nordisk), a long-acting basal insulin that patients inject once per day, and mepolizumab (Nucala®, GlaxoSmithKline), a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5). The scoping documents will be open to public comment for a period of one week.
Members of the public are encouraged to submit suggested refinements or additions to the scoping documents via email to email@example.com. Comments must be received by 5:00 PM PT on Tuesday, October 20 and must adhere to guidelines described in the CTAF public comment guide.
The two reports will form the basis of the February 12 CTAF public meeting, at which an independent Panel will vote on key questions raised in the reports, and policy roundtables will discuss recommendations to apply the evidence to policy and practice.
Additional key dates for the two draft reports, as well as further information about the February meeting, are included below:
Report Timeline and Public Comment Process
An outline of the key dates for the public comment process are outlined below. More information on ICER’s stakeholder engagement policy is available on the CTAF website.
- Oct. 13: Scoping documents posted
- Oct. 13 – 20: Public comment period for scoping documents
- On or about Dec. 16: Draft reports and voting questions posted
- Dec. 16 – Jan. 6: Public comment period for draft reports and voting questions
- On or about Jan. 22: Revised draft reports posted
- Jan. 22 – Feb. 12: CTAF Panel reviews revised draft reports
- Feb. 12: Public meeting
CTAF Meeting Details
Date: February 12, 2016
Location: Bay Area, TBA
Meeting details and registration information will be posted to the CTAF website as they become available.